目的:求证并评价胺碘酮和美托洛尔治疗慢性心功能不全合并室性心律失常的疗效。方法:受试对象均为院内2023年1至12月收治的慢性心功能不全合并室性心律失常患者,排除年龄极端/药物过敏/急性心肌梗死/严重瓣膜性心脏病/甲状腺功能异常/近期接受过心脏手术/病态窦房结综合征/二度或三度房室传导阻滞等患者后,选取80例患者入组,经盲法分至对照组(n = 40,仅予以胺碘酮治疗)与研究组(n = 40),给予胺碘酮和美托洛尔联合治疗。评价两组左心功能评估参数、心肌损伤标志物水平及心输出量与心脏指数水平、心功能分级结果、室性心律失常控制率。结果:较对照组,研究组患者左心室舒张末期及收缩末期内径更小,左心室射血分数更高(P Objective: To confirm and evaluate the efficacy of amiodarone and metoprolol in the treatment of chronic cardiac insufficiency complicated with ventricular arrhythmia. How: All subjects were patients with chronic cardiac insufficiency complicated with ventricular arrhythmia admitted to the hospital from January to December 2023. After excluding patients with extreme age/drug allergy/acute myocardial infarction/severe valvular heart disease/thyroid dysfunction/recent heart surgery/sick sinus syndrome/second or third degree atrioventricular block, 80 patients were selected into the group. They were divided into control group (n = 40, amiodarone treatment only) and study group (n = 40, amiodarone and metoprolol combined treatment) by blind method. Left ventricular function assessment parameters, myocardial injury markers, cardiac output and cardiac index, cardiac function grading results, and ventricular arrhythmia control rate were evaluated in the two groups. Results: Compared with the control group, the left ventricular diameter at the end of diastolic and systolic period in the study group was smaller, the left ventricular ejection fraction was higher (P < 0.05), and the mitral valve flow rate
目的:观察沙库巴曲缬沙坦治疗持续性房颤的临床效果以及对心脏结构的影响。方法:随机选择2023年1月至2023年12月至我院进行治疗的持续性房颤患者110例,使用随机数字法将患者分为观察组和对照组各55例,分别予以沙库巴曲缬沙坦 + 胺碘酮治疗和单独应用胺碘酮治疗。比较两组患者治疗后14 d电复律比例和随访1年复发率、超声检查治疗前后左心室和左心房结构变化,以及血流动力学变化。结果:观察组患者14 d电复律治疗率、6个月和1年房颤复发率分别为20.00%、10.91%和27.27%,均低于对照组的49.49%、25.45%和58.18% (χ2 = 10.292, P = 0.001;χ2 = 3.911, P = 0.048;χ2 = 10.736, P = 0.001)。两组患者治疗前左心房内径(left anterior descending, LAD)、左心房容积(left atrial volume, LAV)、左心房容积指数(left atrial volume index, LAVI)、左心房存储应变(left atrial strain during reservoir phase, LASr)、左心室射血分数(left ventricular ejection fraction, LVEF)、舒张末期内径(left ventricular end diastolic diameter, LVEDD)、收缩末期内径(left ventricular end systolic diameter, LVESD)水平均无明显差异(P > 0.05),治疗1年后,两组患者上述指标与治疗前相比均有组内差异(P P P > 0.05),治疗后两组患者心率与治疗前相比均降低(P t = 8.651;P Objective: To observe the clinical effect of sackubactril valsartan in the treatment of persistent atrial fibrillation and its effect on cardiac structure. Methods: A total of 110 patients with persistent atrial fibrillation who were treated in our hospital from January 2023 to December 2023 were randomly selected and divided into observation group and control group by random number method, 55 patients in each group were treated with sacubactril valsartan + amiodarone or amiodarone alone. The proportion of electro cardioversion at 14 days after treatment, the recurrence rate at 1 year follow-up, the structural changes of left ventricle and left atrium before and af
目的:探讨在冠心病患者中应用曲美他嗪联合阿托伐他汀药物治疗的具体效用,明确其药物应用价值。方法:研究主题时间范围纳入确认为2022年9月~2023年9月,在此时间段确定入我院冠心病心绞痛患者,在符合研究信息标准条件后展开自愿参与筛选,确定60例,双盲法均分,每组各30例,以药物差异命名差别,分别为分析组(曲美他嗪联合阿托伐他汀),对比组(阿托伐他汀),以两组患者治疗前后疾病情况、炎症因子水平、内皮因子水平、治疗效果,作为试验参考数据分析。结果:治疗前,分析组和对比组患者疾病情况、炎症因子水平、内皮因子水平接近(p > 0.05);治疗后,分析组疾病情况、炎症因子水平、内皮因子水平、治疗效果更优(p Objective: This paper aims to investigate the specific efficacy of trimetazidine combined with atorvastatin in the treatment of patients with coronary heart disease, and to clarify its application value. Methods: The subject time range of the study was confirmed to be from September 2022 to September 2023. During this time period, patients with angina pectoris of coronary heart disease admitted to our hospital were identified, and after meeting the research information standard conditions, 60 patients were selected for voluntary screening. The patients were evenly divided by double-blind method, with 30 cases in each group. Naming the differences based on drug differences, they are the analysis group (trimetazidine combined with atorvastatin) and the comparison group (atorvastatin). Disease conditions, levels of inflammatory factors, levels of endothelial factors, and therapeutic effects of patients before and after treatment were used as reference data for trial analysis. Results: Before treatment, the disease status, levels of inflammatory factors and endothelial factors were similar between analysis group and comparison group (p > 0.05). After treatment, the disease status, inflammatory factor level, endothelial fa
